Late Presentation of Linezolid-Induced Serotonin Syndrome After Maprotiline and Mirtazapine Therapy: A Case Report.
Journal
Clinical neuropharmacology
ISSN: 1537-162X
Titre abrégé: Clin Neuropharmacol
Pays: United States
ID NLM: 7607910
Informations de publication
Date de publication:
Historique:
pubmed:
15
1
2021
medline:
26
10
2021
entrez:
14
1
2021
Statut:
ppublish
Résumé
This report describes a 45-year-old man who developed serotonin syndrome on day 13 of linezolid therapy. This is unusual as it typically appears within 24 hours of linezolid initiation. The patient did not receive any serotonergic agents concurrently with linezolid; maprotiline and mirtazapine were stopped 17 days before the development of serotonin syndrome. On day 13 of linezolid administration, the patient exhibited diaphoresis, fever, confusion, agitation, disorientation, anxiety, and restlessness. His blood pressure was elevated with persistent tachycardia. He was then diagnosed with serotonin syndrome using the Hunter criteria. Linezolid was discontinued and supportive measures were initiated, which resulted in the complete resolution of the syndrome. This case report highlights that linezolid-induced serotonin syndrome can occur late in the course of therapy and the importance of the serotonergic agent washout period before the introduction of linezolid. A multidisciplinary team is important for optimal diagnosis and management of such cases.
Identifiants
pubmed: 33443942
doi: 10.1097/WNF.0000000000000431
pii: 00002826-202103000-00007
doi:
Substances chimiques
Serotonin Uptake Inhibitors
0
Maprotiline
2U1W68TROF
Mirtazapine
A051Q2099Q
Linezolid
ISQ9I6J12J
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
71-74Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest and Source of Funding: The authors have no conflicts of interest to declare.
Références
Dosi R, Ambaliya A, Joshi H, et al. Serotonin syndrome versus neuroleptic malignant syndrome: a challenging clinical quandary. BMJ Case Rep 2014;2014:bcr2014204154.
Pharmacia & Upjohn Company. Zyvox (Linezolid) [package insert]. US Food and Drug Administration Web site. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021130s016,021131s013,021132s014lbl.pdf. Accessed October 30, 2019.
Wang B, Dong Y, OHoro J, et al. 1242: ICU-acquired vancomycin-resistant enterococcus: mind the neighbors! Crit Care Med 2018;46:604.
Chuma M, Makishima M, Imai T, et al. Relationship between initial vancomycin trough levels and early-onset vancomycin-associated nephrotoxicity in critically ill patients. Ther Drug Monit 2018;40:109–114.
Walkey AJ, O'Donnell MR, Wiener RS. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 2011;139:1148–1155.
Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016;63:e61–e111.
Ramsey TD, Lau TT, Ensom MH. Serotonergic and adrenergic drug interactions associated with linezolid: a critical review and practical management approach. Ann Pharmacother 2013;47:543–560.
Dunkley EJ, Isbister GK, Sibbritt D, et al. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003;96:635–642.
Kulkarni RR, Kulkarni PR. Linezolid-induced near-fatal serotonin syndrome during escitalopram therapy: case report and review of literature. Indian J Psychol Med 2013;35:413–416.
Wolters Kluwer Clinical Drug Information, Inc. (Lexi-Drugs). Lexicomp Online Web site. Available at: https://online.lexi.com/lco/action/interact. Accessed December 22, 2019.
Mylan Pharmaceuticals Inc.Maprotiline hydrochloride [package insert]. US Food and Drug Administration Web site. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072285s021lbl.pdf. Accessed January 18, 2020.
Ubogu EE, Katirji B. Mirtazapine-induced serotonin syndrome. Clin Neuropharmacol 2003;26:54–57.
Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 2006;42:1578–1583.
Aubanel S, Bruiset F, Chapuis C, et al. Therapeutic options for agitation in the intensive care unit. Anaesth Crit Care Pain Med 2020;39:639–646.
Niven DJ, Laupland KB. Pyrexia: aetiology in the ICU. Crit Care 2016;20:247.